Haleon plc ADR(HLN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:09 PM ET (Korea 10/27 05:09)
Full metrics table
| Index | - | P/E | 20.97 | EPS (ttm) | 0.49 | Insider Own | - | Shs Outstand | 4.40B | Perf Week | 0.59% |
| Market Cap | 44.86B | Forward P/E | 16.7 | EPS next Y | 8.76% | Insider Trans | - | Shs Float | 4.40B | Perf Month | 10.15% |
| Enterprise Value | 54.79B | PEG | 1.84 | EPS next Q | 0.15 | Inst Own | 13.86% | Short Float | 0.56% | Perf Quarter | -0.68% |
| Income | 2.18B | P/S | 3 | EPS this Y | 10.38% | Inst Trans | -1.37% | Short Ratio | 1.64 | Perf Half Y | 7.48% |
| Sales | 14.97B | P/B | 2.06 | EPS next 5Y | 9.06% | ROA | 5.02% | Short Interest | 24.84M | Perf YTD | 0.89% |
| Book/sh | 4.96 | P/C | 40.92 | EPS past 3/5Y | 20.04% 9% | ROE | 9.99% | 52W High | -9.57% ($11.28) | Perf Year | 10.27% |
| Cash/sh | 0.25 | P/FCF | 16.31 | Sales past 3/5Y | 2.82% 2.76% | ROIC | 7.24% | 52W Low | 17.92% ($8.65) | Perf 3Y | 27.66% |
| Dividend Est. | $0.22 (2.12%) | EV/EBITDA | 13.83 | EPS Y/Y TTM | 12.37% | Gross Margin | 65.46% | Volatility(W/M) | 1.56% 1.61% | Perf 5Y | - |
| Dividend TTM | 0.2 | EV/Sales | 3.66 | Sales Y/Y TTM | 4.99% | Oper. Margin | 23.31% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 0.52 | EPS Q/Q | 24561.95% | Profit Margin | 14.55% | RSI (14) | 65.13 | Recom | 2.12 |
| Dividend Gr. 3/5Y | 44.22% - | Current Ratio | 0.69 | Sales Q/Q | 15.22% | SMA20 | 6.95% ($9.54) | Beta | 0.1 | Target Price | $11.15 |
| Payout | 37.42% | Debt/Eq | 0.5 | Earnings | 2026/7/30 | SMA50 | 6.55% ($9.57) | Rel Volume | 1.01 | Prev Close | $10.27 |
| Employees | - | LT Debt/Eq | 0.38 | EPS/Sales Surpr. | 3.63% 1.18% | SMA200 | 4.33% ($9.78) | Avg Volume(3M) | 15.15M | Price | $10.2 |
| IPO | 2022/7/18 | Option/Short | Yes/Yes | Trades | 16462 | Volume | 15,270,714 | Change | -0.68% |
A UK-headquartered comprehensive consumer healthcare company that owns global consumer healthcare brands spanning OTC pharmaceuticals, oral care, and nutritional supplements. It was spun off from its former parent company and stands as the flagship company of a consumer healthcare group that operates numerous global category-leading brands such as Sensodyne, Panadol, Voltaren, Centrum, and Advil.
Over the past 1 year, roughly in the middle
10% below its 1-year high.
Traded about as much as usual. That is 101% of its average volume.
HLN earns moderately but has a weak balance sheet
Of every $100 in sales, $23.31 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.4% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $2,097. Peers typically go for $2,096.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be +27.7%.
Tap to view numbers
The dividend is on the small side
Pays 2.12% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 13.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #3 of 83 in the industry
Based on market cap of $45B.
FAQ
What kind of company is HLN?
HLN belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of HLN?
The market cap of HLN is approximately $44.9B, ranking 344 within its sector.
Does HLN pay dividends?
HLN has a dividend yield of approximately 2.12%, with an annual dividend of $0.22.
What is the P/E ratio of HLN?
HLN has a P/E ratio of approximately 21.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HLN?
HLN has recorded a 52-week high of $11.28 and a low of $8.65.
